The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer
2008

FBP Proteins as Regulators of c-myc in Kidney Cancer

Sample size: 312 publication Evidence: moderate

Author Information

Author(s): Weber Achim, Kristiansen Ilka, Johannsen Manfred, Oelrich Beibei, Scholmann Katharina, Gunia Sven, May Matthias, Meyer Hellmuth-Alexander, Behnke Silvia, Moch Holger, Kristiansen Glen

Primary Institution: University Hospital Zurich, Zurich, Switzerland

Hypothesis

The study investigates the role of FUSE binding proteins FBP1 and FBP3 as regulators of the c-myc proto-oncogene in different types of urogenital cancers.

Conclusion

FBP1 and FBP3 are associated with c-myc up-regulation in renal cell carcinoma, suggesting they act as activators of c-myc in this cancer type.

Supporting Evidence

  • FBP1 and FBP3 were frequently expressed in renal cell carcinoma.
  • High FBP1 expression was associated with c-myc up-regulation in clear cell renal cell carcinoma.
  • FBP1 and FBP3 expression levels were not significantly correlated with prostate and bladder cancers.

Takeaway

FBP1 and FBP3 are proteins that help control a gene called c-myc, which is important for cancer growth, especially in kidney cancer.

Methodology

The expression of FBP1, FBP3, and c-myc was studied in 105 renal cell, 95 prostate, and 112 urinary bladder carcinomas using immunohistochemistry on tissue microarrays.

Limitations

The study primarily focuses on specific cancer types and may not generalize to all cancers.

Participant Demographics

The study included adult patients with renal cell carcinoma, prostate cancer, and bladder cancer.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1186/1471-2407-8-369

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication